Plain-English translation of NCT05268692 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether gemcitabine plus S-1 or gemcitabine plus nab-paclitaxel works better as a pre-surgery chemotherapy treatment for pancreatic cancer. You would receive one of these two drug combinations before your planned surgery to remove the cancer. The goal is to shrink the tumor and improve outcomes after surgery.
Doctors want to know which combination of chemotherapy drugs is most effective when given before surgery for pancreatic cancer. By comparing these two approaches, researchers hope to find the best way to treat this serious cancer and help patients live longer.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive one of the two chemotherapy combinations before your planned pancreatic cancer surgery. You would visit the hospital or clinic regularly to receive the medication and be monitored for side effects. After completing chemotherapy, you would have your planned surgery, and the research team would follow your recovery and outcomes over time.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Japan
Sponsor
Kochi University
Enrollment target
~500 participants
Started
January 2019
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 85 Years
Last updated on clinicaltrials.gov in March 2022.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.